Axon's Rising Costs Reinforce Margin Pressure Concerns

What happened

Axon reported a 35.2% YoY increase in cost of sales and a 20.1% increase in SG&A for Q2 2026, indicating ongoing expense escalation that outpaces the company's historical pattern. This development aligns with the DeepValue report's earlier flag on tariff-driven gross margin erosion and elevated stock-based compensation, which had already led to a GAAP operating loss in FY2025. While revenue growth remains robust, the latest cost data suggests that the expected operating leverage from Axon's software mix shift is not yet materializing as planned. The market had been pricing in sustained high margins, but these cost pressures could undermine the EBITDA margin target of ~25.5% for FY2026 if they persist. Management's guidance for FY2026 already embedded a 15% tariff assumption and $590–620M in SBC, implying that additional cost inflation beyond those estimates would further compress profitability.

Implication

Rising costs at Axon reinforce the DeepValue WAIT rating, as the company's premium valuation leaves little room for margin slippage. If EBITDA margins fall below the guided 25.5%, the stock could re-rate toward the bear case of $380. Conversely, if Axon demonstrates cost controls and sustained high net revenue retention, the bull case of $650 remains possible. The key near-term triggers are the Q3 2026 earnings and Axon Week announcements, which may provide clarity on AI monetization and tariff mitigation. Investors should avoid adding exposure until there is evidence that cost growth is slowing relative to revenue.

Thesis delta

The existing WAIT thesis is reinforced by the new cost data, which confirms operating expenses are rising faster than anticipated. The probability of margin compression increases, but the core investment case hinges on whether Axon can maintain its 125% NRR and convert bookings efficiently. No rating change is warranted yet; we await further quarterly data to validate the margin trajectory.